Physician profile
Adin Boldur
NPI 1619914066
$1,737.03
in general payments reported to CMS, 2019-2025
18 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $75.21 · 2021: $46.74 · 2022: $364 · 2023: $415 · 2024: $313 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $264.54 | 2023-2025 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $241.78 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $212.78 | 2019-2025 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $158.13 | 2019-2025 | |
| Vifor Pharma, INC. | $137.10 | 2022-2025 | Veltassa, Korsuva |
| Baxter Healthcare | $123.52 | 2022 | |
| Nxstage Medical, INC. | $104.01 | 2022 | |
| Horizon Therapeutics Plc | $92.12 | 2023 | Krystexxa |
| Akebia Therapeutics INC | $82.58 | 2019-2025 | Auryxia, Vafseo |
| Amgen INC. | $65.84 | 2021-2024 | Krystexxa |
| Fresenius USA Marketing, INC. | $58.68 | 2020-2024 | Velphoro |
| Novo Nordisk INC | $42.47 | 2023-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $41.96 | 2025 | |
| Calliditas Therapeutics US INC. | $34.90 | 2024-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.85 | 2024 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $19.87 | 2023 | Lupkynis |
| Ardelyx, INC. | $17.59 | 2024 | Ibsrela |
| Opko Pharmaceuticals, LLC | $14.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adin Boldur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.